ClinicalTrials.gov record NCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 23, 2026

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.
Study typeInterventionalA study in which researchers assign participants to one or more interventions, such as a drug, procedure, device, behavioural programme or other approach, to measure their effects.
Age65 years old and older
SexMale
LocationDenmark
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This screening study looks for hidden cardiac amyloidosis in men aged 65 and older who have chest pain but no signs of coronary artery disease. Participants undergo exams such as clinical assessment, blood and urine samples, ECG, echocardiography, and bone scintigraphy; an endomyocardial biopsy may be performed if needed. The study aims to measure how common ATTR cardiac amyloidosis is in this group.

What it is studying. The study is testing how common ATTR cardiac amyloidosis (ATTR-CA) is among older men with chest pain who do not have coronary artery disease, using a set of screening examinations and tests.

What the researchers hope to learn. To determine the prevalence of ATTR cardiac amyloidosis in men over 65 with chest pain and no coronary artery disease and to collect clinical and imaging data that describe these cases.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD). Prior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD. Participants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other
  • Screening thourgh examinations including bonescintigraphy

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • No signs of CAD through Rb-PET and/or CT coronary arteriogram

Exclusion criteria

  • Previous history of amyloidosis

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

The record requires that, before joining, you have already had a CT coronary angiogram or an Rb-PET scan to rule out coronary artery disease; the record does not say these scans are performed by the study. If enrolled, participants will have a clinical examination, give blood and urine samples, and undergo an ECG, an echocardiogram, and bone scintigraphy. The record also states that an endomyocardial biopsy may be conducted if necessary.

How the study is structured. This is an interventional screening study with a single group and no masking. All participants receive the same screening tests (clinical exam, blood and urine samples, ECG, echocardiography, bone scintigraphy) and may have an endomyocardial biopsy if clinically necessary. The main outcome is the prevalence of ATTR-CA measured within about four weeks.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • The registry lists this study under Cardiac Amyloidosis; Chest Pain. Does it apply to my diagnosis?
  • The listed sites are in Denmark. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on ATTRv amyloidosis

This trial is also listed on this site under wild-type ATTR amyloidosis.

Clinical trials106 trials listed for ATTRv amyloidosisEvery trial the registry lists for ATTRv amyloidosis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in ATTRv amyloidosis researchLatest monthly update: September 2026. Includes: Gene-silencing drugs. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Apr 1, 2024
Primary completion
Apr 1, 2027 (estimated)
Study completion
Apr 1, 2027 (estimated)
Target enrollment
300 participants (estimated)
Last updated on registry
Feb 27, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Rigshospitalet, Denmark
Principal investigator
Emil Loldrup Fosbol, MD, Professor, Consultant Cardiologist, DMSc
Rigshospitalet, Denmark

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

Terms used on this page · explanations by MedicalUpdates.ai

observational
A study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
CT
An X-ray scan that builds detailed cross-section images of the body. 'High-resolution' CT (HRCT) is used to look closely at the lungs.
PET scan
A scan in which a small amount of a radioactive tracer is injected so that activity in tissues can be seen. Often combined with a CT or MRI scan.
ECG
A recording of the heart's electrical activity. QTc is one measurement from it; some drugs are avoided if it is prolonged.
echocardiography
An ultrasound scan of the heart. A transesophageal echocardiogram is done through a probe passed into the food pipe for a closer view.
biopsy
Removal of a small piece of tissue so it can be examined under a microscope. 'Biopsy-proven' or 'histologically confirmed' means the diagnosis was confirmed by examining tissue under a microscope.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials